Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870748 · ClinicalTrials.gov registry record · Phase 2
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
A Phase 2 study, sponsored by Sutro Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT05870748 is a Phase 2 study that was terminated before completion, run by Sutro Biopharma. The registered enrollment target is 600 participants.
The verdict
NCT05870748, a Phase 2 study, was terminated before completion, sponsored by Sutro Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Pegylated liposomal doxorubicin
- DRUG Pegfilgrastim
- DRUG Luveltamab tazevibulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05870748
The ClinicalTrials.gov registry entry for NCT05870748 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutro Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT05870748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05870748 about?
NCT05870748 is a clinical study titled "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1". A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
What is the current status of trial NCT05870748?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2023-07-12. Estimated completion is 2025-08-26.
What interventions are being tested in trial NCT05870748?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Pegylated liposomal doxorubicin (DRUG), Pegfilgrastim (DRUG), Luveltamab tazevibulin (DRUG).
Who is sponsoring clinical trial NCT05870748?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.